ShangPharma Opens New Pilot Plant Facility
1/14/2011 8:32:30 AM
(BUSINESS WIRE)--ShangPharma Corporation (NYSE:SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced commencement of operations on the initial phase of production at the Company’s Fengxian facility. This new multi-purpose pharmaceutical development and cGMP manufacturing facility is located in Fengxian in the suburbs of Shanghai, China. The state-of-the-art facility will operate as a wholly owned subsidiary of the Company under the name of China Gateway Pharmaceutical Development Co. Ltd., and will allow the Company to expand its service offering to process research and development, formulation research and development, analytical method development and validation, and cGMP manufacturing of intermediates and APIs.
comments powered by